Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC.JUNS · Entity 8326 | Director | July 31, 2026 | August 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
JUPITER NEUROSCIENCES, INC.
Report date July 31, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.09 · Expires 2036-07-31 | Direct | 472,222 |
Reported balance
After 2026-07-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-31 · Grant · Acquired 472,222 · Balance 472,222 F1: Represents a grant of 472,222 stock options (each representing the right to purchase one share of Common Stock) under the Issuer's 2025 Equity Incentive Plan. The options were granted in connection with the Reporting Person's appointment to the Board of Directors and the options were granted in lieu of cash compensation otherwise payable as an annual board retainer and committee fees. The options vest with 25 % upfront and the remaining vest in 3 quarterly installments beginning February 1, 2026, subject to the Reporting Person's continued service as a director through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of 472,222 stock options (each representing the right to purchase one share of Common Stock) under the Issuer's 2025 Equity Incentive Plan. The options were granted in connection with the Reporting Person's appointment to the Board of Directors and the options were granted in lieu of cash compensation otherwise payable as an annual board retainer and committee fees. The options vest with 25 % upfront and the remaining vest in 3 quarterly installments beginning February 1, 2026, subject to the Reporting Person's continued service as a director through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2026 Filed Aug 5, 2026 20:05 UTC | JUPITER NEUROSCIENCES, INC. JUNS · Entity 8326 | GrantStock Option (right to buy) · Derivative | 472,222 | $0.00 Strike: $0.09 | $0.00 |
DisclosureSEC source: 0001493152-26-036161 · ownership.xml · derivative · entry 1 Cutler Andrew Jon · CIK 0002144263 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 472,222 Underlying: Common Stock · 472,222 shares Expires 2036-07-31 F1 · derivative.exercise_date: Represents a grant of 472,222 stock options (each representing the right to purchase one share of Common Stock) under the Issuer's 2025 Equity Incentive Plan. The options were granted in connection with the Reporting Person's appointment to the Board of Directors and the options were granted in lieu of cash compensation otherwise payable as an annual board retainer and committee fees. The options vest with 25 % upfront and the remaining vest in 3 quarterly installments beginning February 1, 2026, subject to the Reporting Person's continued service as a director through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.